TB-500 (Thymosin Beta-4)
PEPTIDES+ MEMBERS ONLY
INDICATIONS FOR USE
TB-500 is a synthetic peptide derived from thymosin beta-4, a naturally occurring protein found in almost all human cells. It is primarily used off-label to promote tissue repair, reduce inflammation, and improve recovery from musculoskeletal injuries, soft tissue damage, and surgical procedures. It is also investigated for its benefits in managing autoimmune diseases and hair loss.
ROUTE OF ADMINISTRATION
Subcutaneous or intramuscular injection. Systemic injections are typically used for broader therapeutic effects, while localized injections may be used in specific injury sites.
FORMULATIONS AND PRICING
| Formulation | Price |
|---|---|
| 15mg vial (3mg/mL x 5mL) | $130 |
| 30mg vial (6mg/mL x 5mL) | $250 |
COMMON INITIAL DOSING REGIMENS
The typical regimen involves 2–2.5 mg injected subcutaneously or intramuscularly twice weekly for 4–6 weeks, followed by a maintenance dose of 1 mg weekly or as needed.
MECHANISM OF ACTION
TB-500 regulates the actin cytoskeleton within cells, promoting cellular migration and differentiation. This mechanism enhances wound healing, tissue regeneration, and angiogenesis. It also reduces inflammation through modulation of pro-inflammatory cytokines and oxidative stress.
By promoting endothelial cell differentiation, TB-500 contributes to new blood vessel formation, accelerating the healing of injuries such as tendons, ligaments, and skin wounds. Its ability to upregulate keratinocyte and fibroblast activity further aids in wound healing and hair follicle regeneration.
COMMON SIDE EFFECTS
Localized Reactions: Mild pain or redness at the injection site, though rare.
Systemic Effects: Fatigue, headache, or dizziness have been reported but are infrequent.
Immune Response: Some users experience flu-like symptoms initially, possibly due to immune system activation.
Rare Effects: Allergic reactions such as rashes or swelling are uncommon. There are no confirmed reports of significant toxicity with TB-500, but long-term safety data is limited.
CONTRAINDICATIONS
Absolute: Hypersensitivity to BPC-157 or excipients.
Relative: Patients with autoimmune diseases should use BPC-157 cautiously, as immune modulation by peptides could theoretically exacerbate certain conditions. It should also be avoided in pregnant or breastfeeding individuals due to insufficient safety data.
COMPARISON WITH BPC-157
TB-500 and BPC-157 are complementary in their healing mechanisms but differ significantly in their scope of effects. TB-500 specializes in systemic repair by enhancing cellular migration and reducing inflammation, making it ideal for larger injuries or diffuse tissue damage. In contrast, BPC-157 excels in localized healing and gastrointestinal protection.
TB-500 acts more prominently on actin regulation and cellular repair, while BPC-157 focuses on collagen synthesis and angiogenesis. TB-500’s systemic effects may make it more suitable for athletes or patients recovering from extensive injuries, whereas BPC-157 is preferred for targeted treatments or conditions like ulcers and inflammatory bowel disease.
MORE INFORMATION
FDA Safety Data Sheet not available (experimental peptide therapy)